Nucleic Acid Therapeutic Delivery – ZRG1 BBBT (81)

Topics

• Nucleic acid delivery, including CRISPR, siRNA, mRNA, DNA, oligonucleotides, and aptamers.
• Nucleic acid-based vaccine development.
• Gene therapy technology development.
• Design (including AI/ML- based) of delivery vectors and vehicles, including plasmids, viruses (such as AAV), liposomes, micelles, vesicles, nanoparticles, biomaterials, polycationic polymers and lipids, and cells. 
• Development of delivery strategies including light and physical methods (optical caging, electroporation, ultrasound).
• Studies on the biological barriers to nucleic acid delivery (e.g., membrane, tissue, cellular, trafficking, physical). 
• Studies on the interactions between delivery vehicles/ devices and the host tissue (including immune system).

Shared Interests and Overlaps

There are shared interests in drug discovery with Drug and Biologic Therapeutic Delivery (DBTD).  Applications that focus on fundamental aspects of nucleic acid delivery, including intracellular delivery, delivery vehicle development, targeting strategies, and overcoming biological barriers are reviewed in BBBT (81). Applications that emphasize fundamental aspects of therapeutic delivery of cargoes of synthetic and biologic nature except nucleic acids are reviewed in DBTD. 

There are shared interests in gene therapy with Therapeutic Approaches to Genetic Diseases (TAG). Applications that focus on bioengineering aspects of gene therapy technologies are reviewed in BBBT (81). Applications that emphasize development or application of gene therapy for genetic disease  will be reviewed in TAG.  

There are shared interests in nano-therapeutics with Innovations in Nanosystems and Nanotechnology (INN). Applications that focus on biological delivery and targeting issues involving the use of nanocarriers for nucleic acids are reviewed in BBBT (81). Applications that focus on unique features of multifunctional nanoparticles, nanobiomaterials, DNA scaffolds, and delivery and targeting platforms as well as their chemical properties and synthesis are reviewed in INN. 

There are shared interests in therapeutic delivery with Advancing Therapeutics A (ATA). Applications that focus on vehicle development and targeting strategies for nucleic acid, small molecules and biologics are reviewed in BBBT (81).  Applications with a translational focus that include vehicle development and targeting strategies for preclinical cancer therapeutic studies are reviewed in ATA.

There are shared interests in nucleic acid-based therapeutics with Advancing Therapeutics B (ATB).  Applications that emphasize fundamental design, delivery, and targeting of nucleic acid therapies are reviewed in BBBT (81). Applications that emphasize efficacy, safety, or toxicity in animal models or pilot clinical trials are reviewed in ATB.

There are shared interests in therapeutic systems and nuclei acid delivery with the Drug and Biologic Disposition and Toxicity (DBDT). Applications that examine the fundamental aspects of nucleic acid delivery, are reviewed in BBBT (81). Mechanistic and preclinical applications that focus on the disposition and safety and toxicity of delivery agents are reviewed in DBDT.

There are shared interests in mRNA vaccine development with Vaccines Against Infectious Diseases (VID). Applications that emphasize vaccine testing, efficacy, and immune responses may be reviewed in VID. Applications that emphasize novel methods for vaccine delivery, with a focus on bioengineering principles, may be reviewed in BBBT (81).